Cargando…
Towards Automation of Germline Variant Curation in Clinical Cancer Genetics
PURPOSE: Cancer care professionals are confronted with interpreting results from multiplexed gene sequencing of patients at hereditary risk for cancer. Assessments for variant classification now require orthogonal data searches and aggregation of multiple lines of evidence from diverse resources. Th...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6703969/ https://www.ncbi.nlm.nih.gov/pubmed/30787465 http://dx.doi.org/10.1038/s41436-019-0463-8 |
_version_ | 1783445414769328128 |
---|---|
author | Ravichandran, Vignesh Shameer, Zarina Kemel, Yelena Walsh, Michael Cadoo, Karen Lipkin, Steven Mandelker, Diana Zhang, Liying Stadler, Zsofia Robson, Mark Offit, Kenneth Joseph, Vijai |
author_facet | Ravichandran, Vignesh Shameer, Zarina Kemel, Yelena Walsh, Michael Cadoo, Karen Lipkin, Steven Mandelker, Diana Zhang, Liying Stadler, Zsofia Robson, Mark Offit, Kenneth Joseph, Vijai |
author_sort | Ravichandran, Vignesh |
collection | PubMed |
description | PURPOSE: Cancer care professionals are confronted with interpreting results from multiplexed gene sequencing of patients at hereditary risk for cancer. Assessments for variant classification now require orthogonal data searches and aggregation of multiple lines of evidence from diverse resources. The clinical genetics community needs a fast algorithm that automates ACMG based variant classification and provides uniform results. METHODS: Pathogenicity of Mutation Analyzer (PathoMAN) automates germline genomic variant curation from clinical sequencing based on ACMG guidelines. PathoMAN aggregates multiple tracks of genomic, protein and disease specific information from public sources. We compared expertly curated variant data from clinical laboratories to assess performance. RESULTS: PathoMAN achieved a high overall concordance of 94.4% for pathogenic and 81.1% for benign variants. We observed negligible discordance (0.3% pathogenic, 0% benign) when contrasted against expert curated variants. Some loss of resolution (5.3% pathogenic, 18.9% benign) and gain of resolution (1.6% pathogenic, 3.8% benign) was also observed. CONCLUSION: Automation of variant curation enables unbiased, fast, efficient delivery of results in both clinical and laboratory research. We highlight the advantages and weaknesses related to the programmable automation of variant classification. PathoMAN will aid in rapid variant classification by generating robust models using a knowledge-base of diverse genetic data. https://pathoman.mskcc.org |
format | Online Article Text |
id | pubmed-6703969 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
record_format | MEDLINE/PubMed |
spelling | pubmed-67039692019-08-21 Towards Automation of Germline Variant Curation in Clinical Cancer Genetics Ravichandran, Vignesh Shameer, Zarina Kemel, Yelena Walsh, Michael Cadoo, Karen Lipkin, Steven Mandelker, Diana Zhang, Liying Stadler, Zsofia Robson, Mark Offit, Kenneth Joseph, Vijai Genet Med Article PURPOSE: Cancer care professionals are confronted with interpreting results from multiplexed gene sequencing of patients at hereditary risk for cancer. Assessments for variant classification now require orthogonal data searches and aggregation of multiple lines of evidence from diverse resources. The clinical genetics community needs a fast algorithm that automates ACMG based variant classification and provides uniform results. METHODS: Pathogenicity of Mutation Analyzer (PathoMAN) automates germline genomic variant curation from clinical sequencing based on ACMG guidelines. PathoMAN aggregates multiple tracks of genomic, protein and disease specific information from public sources. We compared expertly curated variant data from clinical laboratories to assess performance. RESULTS: PathoMAN achieved a high overall concordance of 94.4% for pathogenic and 81.1% for benign variants. We observed negligible discordance (0.3% pathogenic, 0% benign) when contrasted against expert curated variants. Some loss of resolution (5.3% pathogenic, 18.9% benign) and gain of resolution (1.6% pathogenic, 3.8% benign) was also observed. CONCLUSION: Automation of variant curation enables unbiased, fast, efficient delivery of results in both clinical and laboratory research. We highlight the advantages and weaknesses related to the programmable automation of variant classification. PathoMAN will aid in rapid variant classification by generating robust models using a knowledge-base of diverse genetic data. https://pathoman.mskcc.org 2019-02-21 2019-09 /pmc/articles/PMC6703969/ /pubmed/30787465 http://dx.doi.org/10.1038/s41436-019-0463-8 Text en http://www.nature.com/authors/editorial_policies/license.html#terms Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms |
spellingShingle | Article Ravichandran, Vignesh Shameer, Zarina Kemel, Yelena Walsh, Michael Cadoo, Karen Lipkin, Steven Mandelker, Diana Zhang, Liying Stadler, Zsofia Robson, Mark Offit, Kenneth Joseph, Vijai Towards Automation of Germline Variant Curation in Clinical Cancer Genetics |
title | Towards Automation of Germline Variant Curation in Clinical Cancer Genetics |
title_full | Towards Automation of Germline Variant Curation in Clinical Cancer Genetics |
title_fullStr | Towards Automation of Germline Variant Curation in Clinical Cancer Genetics |
title_full_unstemmed | Towards Automation of Germline Variant Curation in Clinical Cancer Genetics |
title_short | Towards Automation of Germline Variant Curation in Clinical Cancer Genetics |
title_sort | towards automation of germline variant curation in clinical cancer genetics |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6703969/ https://www.ncbi.nlm.nih.gov/pubmed/30787465 http://dx.doi.org/10.1038/s41436-019-0463-8 |
work_keys_str_mv | AT ravichandranvignesh towardsautomationofgermlinevariantcurationinclinicalcancergenetics AT shameerzarina towardsautomationofgermlinevariantcurationinclinicalcancergenetics AT kemelyelena towardsautomationofgermlinevariantcurationinclinicalcancergenetics AT walshmichael towardsautomationofgermlinevariantcurationinclinicalcancergenetics AT cadookaren towardsautomationofgermlinevariantcurationinclinicalcancergenetics AT lipkinsteven towardsautomationofgermlinevariantcurationinclinicalcancergenetics AT mandelkerdiana towardsautomationofgermlinevariantcurationinclinicalcancergenetics AT zhangliying towardsautomationofgermlinevariantcurationinclinicalcancergenetics AT stadlerzsofia towardsautomationofgermlinevariantcurationinclinicalcancergenetics AT robsonmark towardsautomationofgermlinevariantcurationinclinicalcancergenetics AT offitkenneth towardsautomationofgermlinevariantcurationinclinicalcancergenetics AT josephvijai towardsautomationofgermlinevariantcurationinclinicalcancergenetics |